Research
Hormonal
GLP-1 receptor agonists reduce platelet aggregation and thrombus formation, thereby mitigating the risk of thrombotic cardiovascular events in diabetic patients.
GLP-1 agonists may help prevent blood clots by making platelets less sticky, which adds to their heart-protective benefits beyond just sugar control.
GoodSupportsHIGH confidence
GLP 1R stimulation has been linked to an inhibitory effect on platelets, with preclinical studies showing antiaggregation effects on murine and human platelets and reduced clot formation in rodents.
Why this rating
Supported by multiple preclinical studies and some human ex vivo data cited in the review.
Source
Modern antidiabetic therapy by sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and dipeptidyl peptidase 4 inhibitors against cardiovascular diseases
Sebastian Steven et al. · Pharmacological Reviews · 2025
DOI 10.1016/j.pharmr.2025.100082
narrative_reviewCited 12×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.Strong
- SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors provide cardiovascular organ protection in type 2 diabetes through direct antioxidant and anti-inflammatory mechanisms, independent of glucose lowering.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →